Biochemical recurrence of prostate cancer
Prepared with OnCo (onco.cc/prep/prostate-bcr/). Orientation, not medical advice; your team knows your case.
My details
What I know, what is unclear, changes to discuss
Saved in this browserMy questions
16 on the sheet- 1.What is my exact diagnosis, stage, and grade, and which tests established them?
- 2.Which biomarkers have been tested on my tumour (for example PSA and PSA doubling time, PSMA PET, Decipher on the prostatectomy specimen, Interval from local therapy to recurrence), and what were the results?
- 3.Which subtype is my cancer, and does that change the recommended treatment?
- 4.Is germline (inherited) genetic testing recommended for me or my family?
- 5.For my situation (after prostatectomy), which of the standard options do you recommend and why?
- 6.Am I a candidate for Decipher Prostate, and what side effects should I expect?
- 7.For my situation (after radiotherapy, local recurrence), which of the standard options do you recommend and why?
- 8.For my situation (high-risk biochemical recurrence (doubling time under 9 months)), which of the standard options do you recommend and why?
- 9.Am I a candidate for Enzalutamide, Leuprolide (leuprorelin) and GnRH agonists, and what side effects should I expect?
- 10.How do the results of EMBARK apply to someone like me?
- 11.For my situation (psma pet-detected oligorecurrence), which of the standard options do you recommend and why?
- 12.Are there clinical trials I could join, for example of PSMA PET, Enzalutamide, SBRT / SABR (stereotactic radiotherapy), PSMA-PET-guided metastasis-directed therapy as a curative strategy in oligorecurrent prostate cancer?
- 13.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
- 14.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
- 15.I read that “Whether treating PSMA PET-detected metastases early lengthens life or only lowers PSA”. How does that affect my plan?
- 16.I read that “How to spare men with slow doubling times from years of hormone therapy”. How does that affect my plan?
The words I may hear
- Oligometastatic disease: Cancer that has spread to only a few places, which may still be curable by treating each spot.
- PSA (prostate-specific antigen): A blood protein made by the prostate; raised levels prompt further tests, and falling levels show treatment is working.
Tests and results to bring
Biomarker results to ask for: PSA and PSA doubling time, PSMA PET (positive in most men above 0.5 ng/mL), Decipher on the prostatectomy specimen, Interval from local therapy to recurrence.
Scans and tests linked to this cancer: Active surveillance, PSMA PET, RNA sequencing & expression profiling.
Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.
The treatments I may be offered
- High-risk biochemical recurrence (doubling time under 9 months): Enzalutamide with leuprolide, or enzalutamide alone (EMBARK); PSMA PET before starting; intermittent therapy with treatment suspension when PSA becomes undetectable. (Enzalutamide, Leuprolide (leuprorelin) and GnRH agonists, EMBARK, PSMA PET)
- After prostatectomy: Early salvage radiotherapy to the prostate bed, with or without pelvic nodes and four to six months of androgen deprivation for adverse features; observation for slow doubling times. (IMRT / IGRT (modern external beam), Androgen deprivation & AR pathway inhibitors, PSA (prostate-specific antigen), Decipher Prostate)
- After radiotherapy, local recurrence: Salvage prostatectomy, brachytherapy, cryotherapy or high-intensity focused ultrasound in fit men with biopsy-proven local disease and no metastases on PSMA PET. (Robotic & minimally invasive surgery, Brachytherapy, Focused ultrasound & histotripsy, PSMA PET)
- PSMA PET-detected oligorecurrence: Stereotactic radiotherapy to the visible metastases, usually within trials or with hormone therapy; the survival benefit is unproven. (SBRT / SABR (stereotactic radiotherapy), Oligometastatic disease, PSMA-PET-guided metastasis-directed therapy as a curative strategy in oligorecurrent prostate cancer)
From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.